0	11	Interleukin	Interleukin	NNP
12	13	2	2	CD
14	23	signaling	signaling	NN
24	32	involves	involve	VBZ
33	36	the	the	DT
37	52	phosphorylation	phosphorylation	NN
53	55	of	of	IN
56	60	Stat	Stat	NNP
61	69	proteins	protein	NNS
69	70	.	.	.

72	75	One	one	CD
76	78	of	of	IN
79	82	the	the	DT
83	87	most	most	RBS
88	97	important	important	JJ
98	107	cytokines	cytokine	NNS
108	116	involved	involve	VBN
117	119	in	in	IN
120	126	immune	immune	JJ
127	135	response	response	NN
136	146	regulation	regulation	NN
147	149	is	be	VBZ
150	161	interleukin	interleukin	NN
162	163	2	2	CD
164	165	(	(	(
165	169	IL-2	il-2	NN
169	170	)	)	)
170	171	,	,	,
172	173	a	a	DT
174	180	potent	potent	JJ
181	190	activator	activator	NN
191	193	of	of	IN
194	197	the	the	DT
198	211	proliferation	proliferation	NN
212	215	and	and	CC
216	224	function	function	NN
225	227	of	of	IN
228	229	T	t	NN
230	241	lymphocytes	lymphocyte	NNS
242	245	and	and	CC
246	253	natural	natural	JJ
254	260	killer	killer	NN
261	266	cells	cell	NNS
266	267	.	.	.

268	271	The	the	DT
272	282	mechanisms	mechanism	NNS
283	285	by	by	IN
286	291	which	which	WDT
292	295	the	the	DT
296	303	effects	effect	NNS
304	306	of	of	IN
307	311	IL-2	il-2	NN
312	315	are	be	VBP
316	326	propagated	propagate	VBN
327	333	within	within	IN
334	339	cells	cell	NNS
340	343	are	be	VBP
344	347	not	not	RB
348	358	understood	understand	VBN
358	359	.	.	.

360	365	While	while	IN
366	369	the	the	DT
370	377	binding	binding	NN
378	380	of	of	IN
381	385	IL-2	il-2	NN
386	388	to	to	TO
389	392	its	its	PRP$
393	401	receptor	receptor	NN
402	405	was	be	VBD
406	414	recently	recently	RB
415	420	shown	show	VBN
421	423	to	to	TO
424	428	lead	lead	VB
429	431	to	to	TO
432	435	the	the	DT
436	446	activation	activation	NN
447	449	of	of	IN
450	453	two	two	CD
454	461	kinases	kinase	NNS
461	462	,	,	,
463	468	Jak-1	Jak-1	NNP
469	472	and	and	CC
473	478	Jak-3	Jak-3	NNP
478	479	,	,	,
480	490	subsequent	subsequent	JJ
491	496	steps	step	NNS
497	499	in	in	IN
500	503	the	the	DT
504	513	signaling	signaling	NN
514	521	pathway	pathway	NN
522	524	to	to	TO
525	528	the	the	DT
529	536	nucleus	nucleus	NN
537	541	that	that	WDT
542	546	lead	lead	VBP
547	549	to	to	TO
550	553	the	the	DT
554	564	activation	activation	NN
565	567	of	of	IN
568	576	specific	specific	JJ
577	582	genes	gene	NNS
583	586	had	have	VBD
587	590	not	not	RB
591	595	been	be	VBN
596	609	characterized	characterize	VBN
609	610	.	.	.

611	616	Since	since	IN
617	621	many	many	JJ
622	631	cytokines	cytokine	NNS
632	636	that	that	WDT
637	645	activate	activate	VBP
646	649	Jak	Jak	NNP
650	657	kinases	kinase	NNS
658	662	also	also	RB
663	667	lead	lead	VBP
668	670	to	to	TO
671	674	the	the	DT
675	683	tyrosine	tyrosine	NN
684	699	phosphorylation	phosphorylation	NN
700	703	and	and	CC
704	714	activation	activation	NN
715	717	of	of	IN
718	725	members	member	NNS
726	728	of	of	IN
729	732	the	the	DT
733	737	Stat	Stat	NNP
738	744	family	family	NN
745	747	of	of	IN
748	761	transcription	transcription	NN
762	769	factors	factor	NNS
769	770	,	,	,
771	774	the	the	DT
775	782	ability	ability	NN
783	785	of	of	IN
786	790	IL-2	il-2	NN
791	793	to	to	TO
794	801	trigger	trigger	VB
802	806	Stat	Stat	NNP
807	822	phosphorylation	phosphorylation	NN
823	826	was	be	VBD
827	835	examined	examine	VBN
835	836	.	.	.

837	845	Exposure	exposure	NN
846	848	of	of	IN
849	858	activated	activate	VBN
859	864	human	human	JJ
865	866	T	t	NN
867	878	lymphocytes	lymphocyte	NNS
879	881	or	or	CC
882	884	of	of	IN
885	886	a	a	DT
887	894	natural	natural	JJ
895	901	killer	killer	NN
902	906	cell	cell	NN
907	911	line	line	NN
912	913	(	(	(
913	916	NKL	NKL	NNP
916	917	)	)	)
918	920	to	to	TO
921	925	IL-2	il-2	NN
926	931	leads	lead	VBZ
932	934	to	to	TO
935	938	the	the	DT
939	954	phosphorylation	phosphorylation	NN
955	957	of	of	IN
958	963	Stat1	stat1	NN
964	969	alpha	alpha	NN
969	970	,	,	,
971	976	Stat1	stat1	NN
977	981	beta	beta	NN
981	982	,	,	,
983	986	and	and	CC
987	992	Stat3	Stat3	NNP
992	993	,	,	,
994	996	as	as	RB
997	1001	well	well	RB
1002	1004	as	as	IN
1005	1007	of	of	IN
1008	1011	two	two	CD
1012	1024	Stat-related	stat-related	JJ
1025	1033	proteins	protein	NNS
1033	1034	,	,	,
1035	1038	p94	p94	NN
1039	1042	and	and	CC
1043	1047	p95.	p95.	NN
1048	1051	p94	p94	NN
1052	1055	and	and	CC
1056	1059	p95	p95	NN
1060	1065	share	share	NN
1066	1074	homology	homology	NN
1075	1079	with	with	IN
1080	1085	Stat1	stat1	NN
1086	1088	at	at	IN
1089	1092	the	the	DT
1093	1108	phosphorylation	phosphorylation	NN
1109	1113	site	site	NN
1114	1117	and	and	CC
1118	1120	in	in	IN
1121	1124	the	the	DT
1125	1128	Src	Src	NNP
1129	1137	homology	homology	NN
1138	1139	2	2	CD
1140	1141	(	(	(
1141	1144	SH2	sh2	NN
1144	1145	)	)	)
1146	1152	domain	domain	NN
1152	1153	,	,	,
1154	1157	but	but	CC
1158	1167	otherwise	otherwise	RB
1168	1171	are	be	VBP
1172	1187	immunologically	immunologically	RB
1188	1196	distinct	distinct	JJ
1197	1201	from	from	IN
1202	1207	Stat1	Stat1	NNP
1207	1208	.	.	.

1209	1214	These	these	DT
1215	1219	Stat	Stat	NNP
1220	1228	proteins	protein	NNS
1229	1233	were	be	VBD
1234	1239	found	find	VBN
1240	1242	to	to	TO
1243	1254	translocate	translocate	VB
1255	1257	to	to	TO
1258	1261	the	the	DT
1262	1269	nucleus	nucleus	NN
1270	1273	and	and	CC
1274	1276	to	to	TO
1277	1281	bind	bind	VB
1282	1284	to	to	TO
1285	1286	a	a	DT
1287	1295	specific	specific	JJ
1296	1299	DNA	dna	NN
1300	1308	sequence	sequence	NN
1308	1309	.	.	.

1310	1315	These	these	DT
1316	1324	findings	finding	NNS
1325	1332	suggest	suggest	VBP
1333	1334	a	a	DT
1335	1344	mechanism	mechanism	NN
1345	1347	by	by	IN
1348	1353	which	which	WDT
1354	1358	IL-2	il-2	NN
1359	1366	binding	bind	VBG
1367	1369	to	to	TO
1370	1373	its	its	PRP$
1374	1382	receptor	receptor	NN
1383	1386	may	may	MD
1387	1395	activate	activate	VB
1396	1404	specific	specific	JJ
1405	1410	genes	gene	NNS
1411	1419	involved	involve	VBN
1420	1422	in	in	IN
1423	1429	immune	immune	JJ
1430	1434	cell	cell	NN
1435	1443	function	function	NN
1443	1444	.	.	.